Ovarian Serous Cystadenocarcinoma: Correlation between molecular cancer subtypes and selected clinical features
Maintained by TCGA GDAC Team (Broad Institute/Dana-Farber Cancer Institute/Harvard Medical School)
Overview
Introduction

This pipeline computes the correlation between cancer subtypes identified by different molecular patterns and selected clinical features.

Summary

Testing the association between subtypes identified by 12 different clustering approaches and 7 clinical features across 569 patients, 15 significant findings detected with P value < 0.05.

- CNMF clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death' and 'TUMOR.STAGE'.

- Consensus hierarchical clustering analysis on array-based mRNA expression data identified 3 subtypes that correlate to 'Time to Death', 'AGE', 'TUMOR.STAGE', and 'NEOADJUVANT.THERAPY'.

- CNMF clustering analysis on array-based miR expression data identified 3 subtypes that correlate to 'Time to Death'.

- Consensus hierarchical clustering analysis on array-based miR expression data identified 3 subtypes that correlate to 'Time to Death'.

- 3 subtypes identified in current cancer cohort by 'CN CNMF'. These subtypes correlate to 'AGE'.

- 4 subtypes identified in current cancer cohort by 'METHLYATION CNMF'. These subtypes correlate to 'AGE'.

- CNMF clustering analysis on RPPA data identified 3 subtypes that correlate to 'Time to Death'.

- Consensus hierarchical clustering analysis on RPPA data identified 4 subtypes that correlate to 'Time to Death' and 'AGE'.

- CNMF clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that correlate to 'AGE'.

- Consensus hierarchical clustering analysis on sequencing-based mRNA expression data identified 3 subtypes that do not correlate to any clinical features.

- CNMF clustering analysis on sequencing-based miR expression data identified 3 subtypes that correlate to 'Time to Death'.

- Consensus hierarchical clustering analysis on sequencing-based miR expression data identified 3 subtypes that do not correlate to any clinical features.

Results
Overview of the results

Table 1. Get Full Table Overview of the association between subtypes identified by 12 different clustering approaches and 7 clinical features. Shown in the table are P values from statistical tests. Thresholded by P value < 0.05, 15 significant findings detected.

Clinical Features | Time to Death | AGE | PRIMARY SITE OF DISEASE | KARNOFSKY PERFORMANCE SCORE | TUMOR STAGE | RADIATIONS RADIATION REGIMENINDICATION | NEOADJUVANT THERAPY
Statistical Tests | logrank test | ANOVA | Chi-square test | ANOVA | Chi-square test | Fisher's exact test | Fisher's exact test
mRNA CNMF subtypes | 0.00933 | 0.06 | 0.555 | 0.147 | 0.031 | 0.793 | 0.371
mRNA cHierClus subtypes | 0.00116 | 0.00679 | 0.588 | 0.241 | 0.0228 | 0.619 | 0.0475
miR CNMF subtypes | 0.00559 | 0.698 | 0.201 | 0.677 | 0.11 | 0.265 | 0.275
miR cHierClus subtypes | 0.0418 | 0.504 | 0.0908 | 0.547 | 0.0541 | 0.533 | 0.641
CN CNMF | 0.0985 | 3.19e-08 | 0.323 | 0.253 | 0.181 | 0.505 | 0.0759
METHLYATION CNMF | 0.251 | 1.3e-11 | 0.656 | 0.509 | 0.0557 | 0.189 | 0.281
RPPA CNMF subtypes | 0.00128 | 0.58 | 0.885 | 0.61 | 0.333 | 0.129 | 0.586
RPPA cHierClus subtypes | 0.0258 | 0.0408 | 0.676 | 0.68 | 0.181 | 0.823 | 0.201
RNAseq CNMF subtypes | 0.124 | 0.00539 | 1 | 0.104 | 0.648 | 1 | 0.449
RNAseq cHierClus subtypes | 0.122 | 0.128 | 0.536 | 0.104 | 0.119 | 0.618 | 0.47
MIRseq CNMF subtypes | 0.0121 | 0.594 | 0.0583 | 0.207 | 0.193 | 0.476 | 0.546
MIRseq cHierClus subtypes | 0.284 | 0.757 | 0.812 | 0.577 | 0.49 | 0.281 | 0.753

Clustering Approach #1: 'mRNA CNMF subtypes'

Table S1. Get Full Table Description of clustering approach #1: 'mRNA CNMF subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 225 | 207 | 132

'mRNA CNMF subtypes' versus 'Time to Death'

P value = 0.00933 (logrank test)

Table S2. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 559 | 292 | 0.3 - 180.2 (28.3)
subtype1 | 222 | 127 | 0.3 - 152.0 (29.1)
subtype2 | 205 | 90 | 0.4 - 180.2 (27.9)
subtype3 | 132 | 75 | 0.3 - 119.1 (26.7)

Figure S1. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA CNMF subtypes' versus 'AGE'

P value = 0.06 (ANOVA)

Table S3. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 553 | 59.7 (11.6)
subtype1 | 219 | 61.0 (11.6)
subtype2 | 203 | 58.4 (11.3)
subtype3 | 131 | 59.5 (11.9)

Figure S2. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'mRNA CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.555 (Chi-square test)

Table S4. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 560 | 2
subtype1 | 0 | 225 | 0
subtype2 | 1 | 205 | 1
subtype3 | 1 | 130 | 1

Figure S3. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'mRNA CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.147 (ANOVA)

Table S5. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 78 | 75.6 (12.8)
subtype1 | 31 | 78.1 (13.0)
subtype2 | 27 | 76.3 (12.4)
subtype3 | 20 | 71.0 (12.1)

Figure S4. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'mRNA CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.031 (Chi-square test)

Table S6. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 26 | 433 | 85
subtype1 | 7 | 9 | 178 | 29
subtype2 | 9 | 15 | 150 | 32
subtype3 | 0 | 2 | 105 | 24

Figure S5. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'mRNA CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.793 (Fisher's exact test)

Table S7. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 561
subtype1 | 2 | 223
subtype2 | 1 | 206
subtype3 | 0 | 132

Figure S6. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'mRNA CNMF subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.371 (Fisher's exact test)

Table S8. Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 456 | 108
subtype1 | 176 | 49
subtype2 | 173 | 34
subtype3 | 107 | 25

Figure S7. Get High-res Image Clustering Approach #1: 'mRNA CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #2: 'mRNA cHierClus subtypes'

Table S9. Get Full Table Description of clustering approach #2: 'mRNA cHierClus subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 209 | 223 | 132

'mRNA cHierClus subtypes' versus 'Time to Death'

P value = 0.00116 (logrank test)

Table S10. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 559 | 292 | 0.3 - 180.2 (28.3)
subtype1 | 206 | 124 | 0.3 - 152.0 (29.6)
subtype2 | 221 | 87 | 0.5 - 116.1 (27.5)
subtype3 | 132 | 81 | 0.3 - 180.2 (27.6)

Figure S8. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'mRNA cHierClus subtypes' versus 'AGE'

P value = 0.00679 (ANOVA)

Table S11. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 553 | 59.7 (11.6)
subtype1 | 202 | 61.7 (11.5)
subtype2 | 221 | 58.5 (11.0)
subtype3 | 130 | 58.6 (12.4)

Figure S9. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'mRNA cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.588 (Chi-square test)

Table S12. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 560 | 2
subtype1 | 0 | 209 | 0
subtype2 | 1 | 221 | 1
subtype3 | 1 | 130 | 1

Figure S10. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'mRNA cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.241 (ANOVA)

Table S13. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 78 | 75.6 (12.8)
subtype1 | 25 | 79.2 (13.5)
subtype2 | 33 | 73.9 (11.7)
subtype3 | 20 | 74.0 (13.1)

Figure S11. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'mRNA cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.0228 (Chi-square test)

Table S14. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 26 | 433 | 85
subtype1 | 7 | 10 | 165 | 25
subtype2 | 9 | 15 | 162 | 36
subtype3 | 0 | 1 | 106 | 24

Figure S12. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'mRNA cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.619 (Fisher's exact test)

Table S15. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 561
subtype1 | 2 | 207
subtype2 | 1 | 222
subtype3 | 0 | 132

Figure S13. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'mRNA cHierClus subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.0475 (Fisher's exact test)

Table S16. Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 456 | 108
subtype1 | 160 | 49
subtype2 | 191 | 32
subtype3 | 105 | 27

Figure S14. Get High-res Image Clustering Approach #2: 'mRNA cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #3: 'miR CNMF subtypes'

Table S17. Get Full Table Description of clustering approach #3: 'miR CNMF subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 159 | 163 | 240

'miR CNMF subtypes' versus 'Time to Death'

P value = 0.00559 (logrank test)

Table S18. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 557 | 292 | 0.3 - 180.2 (28.2)
subtype1 | 158 | 86 | 0.3 - 130.0 (25.5)
subtype2 | 160 | 92 | 0.3 - 109.7 (24.7)
subtype3 | 239 | 114 | 0.3 - 180.2 (30.1)

Figure S15. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'miR CNMF subtypes' versus 'AGE'

P value = 0.698 (ANOVA)

Table S19. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 551 | 59.7 (11.6)
subtype1 | 155 | 59.0 (12.3)
subtype2 | 160 | 59.8 (11.8)
subtype3 | 236 | 60.1 (11.1)

Figure S16. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #2: 'AGE'

'miR CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.201 (Chi-square test)

Table S20. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 558 | 2
subtype1 | 0 | 157 | 2
subtype2 | 1 | 162 | 0
subtype3 | 1 | 239 | 0

Figure S17. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'miR CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.677 (ANOVA)

Table S21. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 78 | 75.6 (12.8)
subtype1 | 25 | 76.8 (12.5)
subtype2 | 22 | 73.6 (15.6)
subtype3 | 31 | 76.1 (10.9)

Figure S18. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'miR CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.11 (Chi-square test)

Table S22. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 25 | 432 | 85
subtype1 | 3 | 6 | 115 | 33
subtype2 | 7 | 5 | 133 | 17
subtype3 | 6 | 14 | 184 | 35

Figure S19. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'miR CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.265 (Fisher's exact test)

Table S23. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 559
subtype1 | 0 | 159
subtype2 | 0 | 163
subtype3 | 3 | 237

Figure S20. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'miR CNMF subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.275 (Fisher's exact test)

Table S24. Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 454 | 108
subtype1 | 130 | 29
subtype2 | 125 | 38
subtype3 | 199 | 41

Figure S21. Get High-res Image Clustering Approach #3: 'miR CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #4: 'miR cHierClus subtypes'

Table S25. Get Full Table Description of clustering approach #4: 'miR cHierClus subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 200 | 186 | 176

'miR cHierClus subtypes' versus 'Time to Death'

P value = 0.0418 (logrank test)

Table S26. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 557 | 292 | 0.3 - 180.2 (28.2)
subtype1 | 197 | 95 | 0.3 - 180.2 (29.0)
subtype2 | 184 | 99 | 0.5 - 152.0 (29.0)
subtype3 | 176 | 98 | 0.3 - 130.0 (24.6)

Figure S22. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'miR cHierClus subtypes' versus 'AGE'

P value = 0.504 (ANOVA)

Table S27. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 551 | 59.7 (11.6)
subtype1 | 198 | 60.0 (11.8)
subtype2 | 181 | 60.2 (11.0)
subtype3 | 172 | 58.8 (12.2)

Figure S23. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'miR cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.0908 (Chi-square test)

Table S28. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 558 | 2
subtype1 | 2 | 198 | 0
subtype2 | 0 | 186 | 0
subtype3 | 0 | 174 | 2

Figure S24. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'miR cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.547 (ANOVA)

Table S29. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 78 | 75.6 (12.8)
subtype1 | 31 | 76.1 (13.1)
subtype2 | 20 | 73.0 (13.4)
subtype3 | 27 | 77.0 (12.0)

Figure S25. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'miR cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.0541 (Chi-square test)

Table S30. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 25 | 432 | 85
subtype1 | 4 | 9 | 152 | 33
subtype2 | 9 | 10 | 149 | 17
subtype3 | 3 | 6 | 131 | 35

Figure S26. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'miR cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.533 (Fisher's exact test)

Table S31. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 559
subtype1 | 1 | 199
subtype2 | 2 | 184
subtype3 | 0 | 176

Figure S27. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'miR cHierClus subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.641 (Fisher's exact test)

Table S32. Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 454 | 108
subtype1 | 164 | 36
subtype2 | 146 | 40
subtype3 | 144 | 32

Figure S28. Get High-res Image Clustering Approach #4: 'miR cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #5: 'CN CNMF'

Table S33. Get Full Table Description of clustering approach #5: 'CN CNMF'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 157 | 195 | 202

'CN CNMF' versus 'Time to Death'

P value = 0.0985 (logrank test)

Table S34. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 548 | 285 | 0.3 - 180.2 (28.3)
subtype1 | 155 | 86 | 1.2 - 119.1 (29.5)
subtype2 | 194 | 94 | 0.3 - 130.0 (30.2)
subtype3 | 199 | 105 | 0.3 - 180.2 (22.3)

Figure S29. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #1: 'Time to Death'

'CN CNMF' versus 'AGE'

P value = 3.19e-08 (ANOVA)

Table S35. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 543 | 59.8 (11.6)
subtype1 | 153 | 59.6 (12.4)
subtype2 | 194 | 56.4 (11.0)
subtype3 | 196 | 63.2 (10.6)

Figure S30. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #2: 'AGE'

'CN CNMF' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.323 (Chi-square test)

Table S36. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 550 | 2
subtype1 | 1 | 156 | 0
subtype2 | 1 | 194 | 0
subtype3 | 0 | 200 | 2

Figure S31. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'CN CNMF' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.253 (ANOVA)

Table S37. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 76 | 75.5 (12.9)
subtype1 | 19 | 77.9 (11.3)
subtype2 | 29 | 72.4 (12.4)
subtype3 | 28 | 77.1 (14.1)

Figure S32. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'CN CNMF' versus 'TUMOR.STAGE'

P value = 0.181 (Chi-square test)

Table S38. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 26 | 425 | 82
subtype1 | 7 | 7 | 118 | 23
subtype2 | 3 | 10 | 144 | 38
subtype3 | 6 | 9 | 163 | 21

Figure S33. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

'CN CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.505 (Fisher's exact test)

Table S39. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 551
subtype1 | 1 | 156
subtype2 | 0 | 195
subtype3 | 2 | 200

Figure S34. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'CN CNMF' versus 'NEOADJUVANT.THERAPY'

P value = 0.0759 (Fisher's exact test)

Table S40. Clustering Approach #5: 'CN CNMF' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 450 | 104
subtype1 | 128 | 29
subtype2 | 167 | 28
subtype3 | 155 | 47

Figure S35. Get High-res Image Clustering Approach #5: 'CN CNMF' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #6: 'METHLYATION CNMF'

Table S41. Get Full Table Description of clustering approach #6: 'METHLYATION CNMF'

Cluster Labels | 1 | 2 | 3 | 4
--- | --- | --- | --- | ---
Number of samples | 105 | 137 | 151 | 156

'METHLYATION CNMF' versus 'Time to Death'

P value = 0.251 (logrank test)

Table S42. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 543 | 290 | 0.3 - 180.2 (29.0)
subtype1 | 102 | 48 | 0.4 - 130.0 (23.5)
subtype2 | 135 | 78 | 0.8 - 125.7 (29.1)
subtype3 | 150 | 80 | 0.3 - 180.2 (30.3)
subtype4 | 156 | 84 | 0.3 - 152.0 (29.4)

Figure S36. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #1: 'Time to Death'

'METHLYATION CNMF' versus 'AGE'

P value = 1.3e-11 (ANOVA)

Table S43. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 539 | 59.7 (11.7)
subtype1 | 104 | 58.3 (12.5)
subtype2 | 134 | 64.5 (11.0)
subtype3 | 147 | 54.9 (11.2)
subtype4 | 154 | 61.1 (10.2)

Figure S37. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #2: 'AGE'

'METHLYATION CNMF' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.656 (Chi-square test)

Table S44. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 545 | 2
subtype1 | 1 | 104 | 0
subtype2 | 0 | 136 | 1
subtype3 | 0 | 151 | 0
subtype4 | 1 | 154 | 1

Figure S38. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'METHLYATION CNMF' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.509 (ANOVA)

Table S45. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 78 | 75.6 (12.8)
subtype1 | 19 | 72.6 (13.7)
subtype2 | 19 | 75.8 (15.7)
subtype3 | 19 | 78.9 (8.1)
subtype4 | 21 | 75.2 (12.5)

Figure S39. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'METHLYATION CNMF' versus 'TUMOR.STAGE'

P value = 0.0557 (Chi-square test)

Table S46. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 16 | 24 | 421 | 83
subtype1 | 2 | 5 | 77 | 19
subtype2 | 5 | 4 | 114 | 11
subtype3 | 5 | 4 | 109 | 33
subtype4 | 4 | 11 | 121 | 20

Figure S40. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #5: 'TUMOR.STAGE'

'METHLYATION CNMF' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.189 (Fisher's exact test)

Table S47. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 546
subtype1 | 1 | 104
subtype2 | 2 | 135
subtype3 | 0 | 151
subtype4 | 0 | 156

Figure S41. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'METHLYATION CNMF' versus 'NEOADJUVANT.THERAPY'

P value = 0.281 (Fisher's exact test)

Table S48. Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 441 | 108
subtype1 | 84 | 21
subtype2 | 106 | 31
subtype3 | 129 | 22
subtype4 | 122 | 34

Figure S42. Get High-res Image Clustering Approach #6: 'METHLYATION CNMF' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #7: 'RPPA CNMF subtypes'

Table S49. Get Full Table Description of clustering approach #7: 'RPPA CNMF subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 128 | 207 | 72

'RPPA CNMF subtypes' versus 'Time to Death'

P value = 0.00128 (logrank test)

Table S50. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 400 | 209 | 0.3 - 180.2 (28.6)
subtype1 | 125 | 71 | 0.4 - 125.7 (31.1)
subtype2 | 204 | 92 | 0.3 - 180.2 (25.2)
subtype3 | 71 | 46 | 0.5 - 89.3 (25.9)

Figure S43. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA CNMF subtypes' versus 'AGE'

P value = 0.58 (ANOVA)

Table S51. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 400 | 59.7 (11.8)
subtype1 | 126 | 60.0 (12.3)
subtype2 | 204 | 59.1 (11.7)
subtype3 | 70 | 60.7 (11.3)

Figure S44. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RPPA CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.885 (Chi-square test)

Table S52. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 403 | 2
subtype1 | 1 | 126 | 1
subtype2 | 1 | 205 | 1
subtype3 | 0 | 72 | 0

Figure S45. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RPPA CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.61 (ANOVA)

Table S53. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 51 | 74.9 (11.9)
subtype1 | 19 | 76.8 (10.0)
subtype2 | 27 | 73.3 (13.6)
subtype3 | 5 | 76.0 (8.9)

Figure S46. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RPPA CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.333 (Chi-square test)

Table S54. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 14 | 19 | 317 | 52
subtype1 | 4 | 7 | 96 | 20
subtype2 | 9 | 11 | 164 | 20
subtype3 | 1 | 1 | 57 | 12

Figure S47. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RPPA CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.129 (Fisher's exact test)

Table S55. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 2 | 405
subtype1 | 2 | 126
subtype2 | 0 | 207
subtype3 | 0 | 72

Figure S48. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RPPA CNMF subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.586 (Fisher's exact test)

Table S56. Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 334 | 73
subtype1 | 106 | 22
subtype2 | 172 | 35
subtype3 | 56 | 16

Figure S49. Get High-res Image Clustering Approach #7: 'RPPA CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #8: 'RPPA cHierClus subtypes'

Table S57. Get Full Table Description of clustering approach #8: 'RPPA cHierClus subtypes'

Cluster Labels | 1 | 2 | 3 | 4
--- | --- | --- | --- | ---
Number of samples | 101 | 68 | 145 | 93

'RPPA cHierClus subtypes' versus 'Time to Death'

P value = 0.0258 (logrank test)

Table S58. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 400 | 209 | 0.3 - 180.2 (28.6)
subtype1 | 97 | 45 | 0.3 - 115.9 (28.5)
subtype2 | 68 | 42 | 0.8 - 180.2 (35.5)
subtype3 | 143 | 84 | 0.4 - 125.7 (27.5)
subtype4 | 92 | 38 | 0.5 - 152.0 (22.6)

Figure S50. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RPPA cHierClus subtypes' versus 'AGE'

P value = 0.0408 (ANOVA)

Table S59. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 400 | 59.7 (11.8)
subtype1 | 100 | 57.7 (11.8)
subtype2 | 67 | 61.5 (11.1)
subtype3 | 142 | 61.2 (12.1)
subtype4 | 91 | 58.2 (11.6)

Figure S51. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RPPA cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.676 (Chi-square test)

Table S60. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 403 | 2
subtype1 | 0 | 101 | 0
subtype2 | 1 | 67 | 0
subtype3 | 1 | 143 | 1
subtype4 | 0 | 92 | 1

Figure S52. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RPPA cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.68 (ANOVA)

Table S61. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 51 | 74.9 (11.9)
subtype1 | 5 | 80.0 (0.0)
subtype2 | 9 | 75.6 (16.7)
subtype3 | 13 | 72.3 (10.1)
subtype4 | 24 | 75.0 (12.2)

Figure S53. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RPPA cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.181 (Chi-square test)

Table S62. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | I | II | III | IV
--- | --- | --- | --- | ---
ALL | 14 | 19 | 317 | 52
subtype1 | 8 | 5 | 76 | 9
subtype2 | 2 | 4 | 53 | 9
subtype3 | 3 | 5 | 111 | 24
subtype4 | 1 | 5 | 77 | 10

Figure S54. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RPPA cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.823 (Fisher's exact test)

Table S63. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 2 | 405
subtype1 | 0 | 101
subtype2 | 0 | 68
subtype3 | 1 | 144
subtype4 | 1 | 92

Figure S55. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RPPA cHierClus subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.201 (Fisher's exact test)

Table S64. Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 334 | 73
subtype1 | 80 | 21
subtype2 | 54 | 14
subtype3 | 117 | 28
subtype4 | 83 | 10

Figure S56. Get High-res Image Clustering Approach #8: 'RPPA cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #9: 'RNAseq CNMF subtypes'

Table S65. Get Full Table Description of clustering approach #9: 'RNAseq CNMF subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 103 | 69 | 91

'RNAseq CNMF subtypes' versus 'Time to Death'

P value = 0.124 (logrank test)

Table S66. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 261 | 147 | 0.3 - 180.2 (28.2)
subtype1 | 103 | 55 | 0.4 - 180.2 (28.2)
subtype2 | 68 | 36 | 1.0 - 106.0 (34.6)
subtype3 | 90 | 56 | 0.3 - 152.0 (25.0)

Figure S57. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq CNMF subtypes' versus 'AGE'

P value = 0.00539 (ANOVA)

Table S67. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 256 | 59.1 (10.8)
subtype1 | 100 | 59.2 (10.3)
subtype2 | 68 | 55.8 (10.9)
subtype3 | 88 | 61.4 (10.9)

Figure S58. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 1 (Fisher's exact test)

Table S68. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY
--- | --- | ---
ALL | 1 | 262
subtype1 | 1 | 102
subtype2 | 0 | 69
subtype3 | 0 | 91

Figure S59. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RNAseq CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.104 (ANOVA)

Table S69. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 15 | 74.7 (11.9)
subtype1 | 10 | 72.0 (14.0)
subtype2 | 3 | 80.0 (0.0)
subtype3 | 2 | 80.0 (0.0)

Figure S60. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RNAseq CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.648 (Chi-square test)

Table S70. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | II | III | IV
--- | --- | --- | ---
ALL | 18 | 211 | 33
subtype1 | 8 | 81 | 14
subtype2 | 5 | 53 | 11
subtype3 | 5 | 77 | 8

Figure S61. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RNAseq CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 1 (Fisher's exact test)

Table S71. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 2 | 261
subtype1 | 1 | 102
subtype2 | 0 | 69
subtype3 | 1 | 90

Figure S62. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RNAseq CNMF subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.449 (Fisher's exact test)

Table S72. Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 211 | 52
subtype1 | 83 | 20
subtype2 | 52 | 17
subtype3 | 76 | 15

Figure S63. Get High-res Image Clustering Approach #9: 'RNAseq CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #10: 'RNAseq cHierClus subtypes'

Table S73. Get Full Table Description of clustering approach #10: 'RNAseq cHierClus subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 33 | 108 | 122

'RNAseq cHierClus subtypes' versus 'Time to Death'

P value = 0.122 (logrank test)

Table S74. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 261 | 147 | 0.3 - 180.2 (28.2)
subtype1 | 33 | 16 | 0.3 - 116.1 (26.9)
subtype2 | 107 | 58 | 0.4 - 180.2 (27.5)
subtype3 | 121 | 73 | 0.4 - 152.0 (30.0)

Figure S64. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'RNAseq cHierClus subtypes' versus 'AGE'

P value = 0.128 (ANOVA)

Table S75. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 256 | 59.1 (10.8)
subtype1 | 32 | 56.1 (11.2)
subtype2 | 105 | 58.6 (10.4)
subtype3 | 119 | 60.3 (11.0)

Figure S65. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'RNAseq cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.536 (Fisher's exact test)

Table S76. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY
--- | --- | ---
ALL | 1 | 262
subtype1 | 0 | 33
subtype2 | 1 | 107
subtype3 | 0 | 122

Figure S66. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'RNAseq cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.104 (ANOVA)

Table S77. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 15 | 74.7 (11.9)
subtype2 | 11 | 72.7 (13.5)
subtype3 | 4 | 80.0 (0.0)

Figure S67. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'RNAseq cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.119 (Chi-square test)

Table S78. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | II | III | IV
--- | --- | --- | ---
ALL | 18 | 211 | 33
subtype1 | 4 | 22 | 7
subtype2 | 5 | 87 | 16
subtype3 | 9 | 102 | 10

Figure S68. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'RNAseq cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.618 (Fisher's exact test)

Table S79. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 2 | 261
subtype1 | 0 | 33
subtype2 | 0 | 108
subtype3 | 2 | 120

Figure S69. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'RNAseq cHierClus subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.47 (Fisher's exact test)

Table S80. Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 211 | 52
subtype1 | 24 | 9
subtype2 | 87 | 21
subtype3 | 100 | 22

Figure S70. Get High-res Image Clustering Approach #10: 'RNAseq cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #11: 'MIRseq CNMF subtypes'

Table S81. Get Full Table Description of clustering approach #11: 'MIRseq CNMF subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 113 | 195 | 146

'MIRseq CNMF subtypes' versus 'Time to Death'

P value = 0.0121 (logrank test)

Table S82. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 451 | 252 | 0.3 - 180.2 (30.1)
subtype1 | 113 | 74 | 0.3 - 152.0 (27.0)
subtype2 | 194 | 101 | 0.3 - 180.2 (32.5)
subtype3 | 144 | 77 | 0.3 - 130.0 (28.7)

Figure S71. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq CNMF subtypes' versus 'AGE'

P value = 0.594 (ANOVA)

Table S83. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 446 | 59.8 (11.5)
subtype1 | 112 | 60.8 (11.7)
subtype2 | 192 | 59.5 (11.3)
subtype3 | 142 | 59.5 (11.6)

Figure S72. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq CNMF subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.0583 (Chi-square test)

Table S84. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 451 | 1
subtype1 | 2 | 110 | 1
subtype2 | 0 | 195 | 0
subtype3 | 0 | 146 | 0

Figure S73. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'MIRseq CNMF subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.207 (ANOVA)

Table S85. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 64 | 75.3 (13.2)
subtype1 | 10 | 82.0 (14.8)
subtype2 | 46 | 74.3 (12.4)
subtype3 | 8 | 72.5 (14.9)

Figure S74. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'MIRseq CNMF subtypes' versus 'TUMOR.STAGE'

P value = 0.193 (Chi-square test)

Table S86. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | II | III | IV
--- | --- | --- | ---
ALL | 24 | 352 | 74
subtype1 | 4 | 91 | 17
subtype2 | 8 | 147 | 38
subtype3 | 12 | 114 | 19

Figure S75. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'MIRseq CNMF subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.476 (Fisher's exact test)

Table S87. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 451
subtype1 | 0 | 113
subtype2 | 1 | 194
subtype3 | 2 | 144

Figure S76. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRseq CNMF subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.546 (Fisher's exact test)

Table S88. Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 367 | 87
subtype1 | 89 | 24
subtype2 | 162 | 33
subtype3 | 116 | 30

Figure S77. Get High-res Image Clustering Approach #11: 'MIRseq CNMF subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Clustering Approach #12: 'MIRseq cHierClus subtypes'

Table S89. Get Full Table Description of clustering approach #12: 'MIRseq cHierClus subtypes'

Cluster Labels | 1 | 2 | 3
--- | --- | --- | ---
Number of samples | 3 | 153 | 298

'MIRseq cHierClus subtypes' versus 'Time to Death'

P value = 0.284 (logrank test)

Table S90. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

| nPatients | nDeath | Duration Range (Median), Month
--- | --- | --- | ---
ALL | 451 | 252 | 0.3 - 180.2 (30.1)
subtype1 | 3 | 3 | 4.5 - 60.6 (33.7)
subtype2 | 151 | 82 | 0.3 - 130.0 (28.6)
subtype3 | 297 | 167 | 0.3 - 180.2 (31.0)

Figure S78. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #1: 'Time to Death'

'MIRseq cHierClus subtypes' versus 'AGE'

P value = 0.757 (ANOVA)

Table S91. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 446 | 59.8 (11.5)
subtype1 | 3 | 62.7 (1.5)
subtype2 | 149 | 59.3 (11.9)
subtype3 | 294 | 60.0 (11.4)

Figure S79. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #2: 'AGE'

'MIRseq cHierClus subtypes' versus 'PRIMARY.SITE.OF.DISEASE'

P value = 0.812 (Chi-square test)

Table S92. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

nPatients | OMENTUM | OVARY | PERITONEUM (OVARY)
--- | --- | --- | ---
ALL | 2 | 451 | 1
subtype1 | 0 | 3 | 0
subtype2 | 0 | 153 | 0
subtype3 | 2 | 295 | 1

Figure S80. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #3: 'PRIMARY.SITE.OF.DISEASE'

'MIRseq cHierClus subtypes' versus 'KARNOFSKY.PERFORMANCE.SCORE'

P value = 0.577 (ANOVA)

Table S93. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

| nPatients | Mean (Std.Dev)
--- | --- | ---
ALL | 64 | 75.3 (13.2)
subtype2 | 8 | 72.5 (14.9)
subtype3 | 56 | 75.7 (13.1)

Figure S81. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #4: 'KARNOFSKY.PERFORMANCE.SCORE'

'MIRseq cHierClus subtypes' versus 'TUMOR.STAGE'

P value = 0.49 (Chi-square test)

Table S94. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

nPatients | II | III | IV
--- | --- | --- | ---
ALL | 24 | 352 | 74
subtype1 | 0 | 3 | 0
subtype2 | 11 | 120 | 21
subtype3 | 13 | 229 | 53

Figure S82. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #5: 'TUMOR.STAGE'

'MIRseq cHierClus subtypes' versus 'RADIATIONS.RADIATION.REGIMENINDICATION'

P value = 0.281 (Fisher's exact test)

Table S95. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

nPatients | NO | YES
--- | --- | ---
ALL | 3 | 451
subtype1 | 0 | 3
subtype2 | 2 | 151
subtype3 | 1 | 297

Figure S83. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #6: 'RADIATIONS.RADIATION.REGIMENINDICATION'

'MIRseq cHierClus subtypes' versus 'NEOADJUVANT.THERAPY'

P value = 0.753 (Fisher's exact test)

Table S96. Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

nPatients | NO | YES
--- | --- | ---
ALL | 367 | 87
subtype1 | 3 | 0
subtype2 | 121 | 32
subtype3 | 243 | 55

Figure S84. Get High-res Image Clustering Approach #12: 'MIRseq cHierClus subtypes' versus Clinical Feature #7: 'NEOADJUVANT.THERAPY'

Methods & Data
Input

- Cluster data file = OV.mergedcluster.txt

- Clinical data file = OV.clin.merged.picked.txt

- Number of patients = 569

- Number of clustering approaches = 12

- Number of selected clinical features = 7

- Exclude small clusters that include fewer than K patients, K = 3

Clustering approaches
CNMF clustering

consensus non-negative matrix factorization clustering approach (Brunet et al. 2004)

Consensus hierarchical clustering

Resampling-based clustering method (Monti et al. 2003)

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

ANOVA analysis

For continuous numerical clinical features, one-way analysis of variance (Howell 2002) was applied to compare the clinical values between tumor subtypes using 'anova' function in R

Chi-square test

For multi-class clinical features (nominal or ordinal), Chi-square tests (Greenwood and Nikulin 1996) were used to estimate the P values using the 'chisq.test' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] Brunet et al., Metagenes and molecular pattern discovery using matrix factorization, PNAS 101(12):4164-9 (2004)
[2] Monti et al., Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data, Machine Learning 52(1):91-118 (2003)
[3] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[4] Howell, D, Statistical Methods for Psychology. (5th ed.), Duxbury Press:324-5 (2002)
[5] Greenwood and Nikulin, A guide to chi-squared testing, Wiley, New York. ISBN 047155779X (1996)
[6] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
Copyright © 2012 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle